KMA and Co.
  • Why
  • Who
  • What
  • Where
  • Case Studies
  • Thought Leadership
  • Blog
Select Page
Digital Therapeutics is Primed for a Return to the Roaring 20’s

Digital Therapeutics is Primed for a Return to the Roaring 20’s

by Cassie Arnold | Apr 20, 2021 | Deal making, Digital Health, Digital Therapeutic, Investment, Modern Work, Venture capital

For 2021, our data partner DealForma is providing venture investment data in addition to the data they have been sharing on M&A deals.  As we all know, VC investment was on a roll in 2020. Silicon Valley Bank has reported that venture investment in...
Counting Deals Instead of Votes

Counting Deals Instead of Votes

by Cassie Arnold | Nov 10, 2020 | Biotech Finance, Deal making, Digital Health, Digital Therapeutic

Tired from a long week of parsing electoral college votes? How about focusing on digital therapeutic deals for a change of pace? The third quarter brought a record number of digital therapeutic deals with a total of 19. That’s up from 16 in the previous quarter. The...
Acquisitions Fuel Digital Therapeutic Dealmaking in Q2

Acquisitions Fuel Digital Therapeutic Dealmaking in Q2

by Cassie Arnold | Jul 8, 2020 | Deal making, Digital Health, Digital Therapeutic, Investment

Digital therapeutic dealmaking bounced back to Q4 2019 levels in the second quarter of the year. After a first quarter where deal-making was stymied in by the onslaught of COVID-19, buyers came back big-time in the second quarter once the reality of the “new...
Digital Therapeutic Deals in a Time of COVID-19

Digital Therapeutic Deals in a Time of COVID-19

by Cassie Arnold | Apr 21, 2020 | Deal making, Digital Health, Digital Therapeutic, Investment

First quarter digital therapeutic deal data provided by DealForma shows a drop quarter-over-quarter from 16 transactions in the last quarter of 2019 to 11 in the first quarter of 2020. But year-over-year, the first quarter of 2020 is on par with the first quarter of...
Tracking Digital Therapeutics

Tracking Digital Therapeutics

by Cassie Arnold | Feb 25, 2020 | Biotech Finance, Digital Health, Digital Therapeutic

When I started following the digital health sector in earnest about ten years ago, I was intrigued with the potential of digital technology to treat disease – the so-called digital therapeutics. Instead, the sector produced an almost infinite variety of activity...

Recent Posts

  • Five Bits of Advice on MarCom Tactics
  • TL;DR*, Less is More, Short and Sweet
  • Digital Therapeutic Investment Soars — is there a bubble in our future?
  • Digital Therapeutics is Primed for a Return to the Roaring 20’s
  • In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

Archives

  • March 2022
  • August 2021
  • July 2021
  • April 2021
  • February 2021
  • January 2021
  • November 2020
  • August 2020
  • July 2020
  • April 2020
  • February 2020
  • November 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • April 2019
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • March 2018
  • February 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • September 2016
  • August 2016
  • April 2016
  • March 2016
  • February 2016
  • December 2015
  • October 2015
  • June 2015
  • April 2015
  • March 2015
  • February 2015
  • November 2014
  • October 2014
  • August 2014
  • June 2014

Categories

  • 21st Century Culture
  • Advertising
  • Biotech Finance
  • Branding
  • Communications
  • COVID
  • Deal making
  • Digital Health
  • Digital Therapeutic
  • Digital Therapeutics
  • Gender at Work
  • Investment
  • Modern Work
  • Persuasion
  • Sales
  • Uncategorized
  • Venture capital
  • Twitter
  • RSS
© 2021 KMA & Company